Key Points. Pfizer's earnings growth and dividends could be enough to deliver a total return of more than 100% over the next five years.. Two wild cards hold the potential to boost Pfizer's prospects of doubling even more.. Several risks could prevent the stock from doubling, however, including patent expirations and potential pipeline setbacks.. Stock prices follow earnings. Adjusted earnings projected to increase by risk adjusted compound annual growth rate in the double digits thru 2025. Earnings + juicy dividends= investors wet dream. The projected growth rate is actually a pessimistic projection as it does not include the effects of the covid 19 vax. Projected covid earnings alone= 33.5 billion this year (not including a recent order of 200 million doses by the US government. PFE total return has doubled over the last 8 years while being weighed down by declining sales and old drugs losing patents etc.. New covid variants could drive the need for more vaccines and PFE an Moderna are best set for profits if this happens. Oral antiviral drug Pfizer has developed will come soon and be big for earnings. Pfizer will use Q2 earnings to continue to pursue business development according to CEO. Cons. Some key patents expire in 2025-2026. Covid earnings could diminish in coming years as world gets a better handle on the virus. https://www.fool.com/investing/2021/08/09/buying-pfizer-stock-now-could-double-your-money-wi/